Trial reportThe oncologist2026
A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.
Trial report in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03055013 (A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe GRade, Age, Nodes and Tumor (GRANT) score is one of the prognostic models recommended by international guidelines to refine recurrence risk stratification in patients with surgically treated renal cell carcinoma (RCC) and integrates age, tumor size, grade, and nodal status. In this study, we aimed to validate the GRANT score within the ECOG-ACRIN EA8143 PROSPER prospective trial.
methodsWe conducted a validation analysis of the GRANT score within the phase III randomized EA8143 PROSPER study of perioperative nivolumab in surgically treated RCC. Patients were classified into 2 risk groups, favorable (0-1 risk factors) versus unfavorable (2-4 risk factors). Relapse-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Model discrimination were evaluated using Harrell's C-index.
resultsAmong 714 patients included, 58.3% were favorable and 41.7% unfavorable based on the GRANT score. Patients in the favorable group had a significantly longer median RFS (61.1 vs. 36.9 months; hazard ratio [HR]: 0.36, 95% confidence interval [CI]: 0.27-0.48, P < .001) and OS (median not reached, HR: 0.25, 95% CI: 0.15-0.42, P < .001) compared to patients in the unfavorable group. The c-index was 0.63 and 0.66 for RFS and OS, respectively. A better prognostic performance was observed among nonclear cell RCC for both RFS (HR: 0.13, 95% CI: 0.05-0.33, P < .001; c-index: 0.74) and OS (HR: 0.14, 95% CI: 0.04-0.50, P < .001; c-index 0.74).
conclusionsThe GRANT score was prospectively validated in the PROSPER study, demonstrating prognostic value for both RFS and OS, especially in nonclear RCC, further supporting its use in clinical practice. Clinical trial registration number: ClinicalTrials.gov, NCT03055013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.